iShares Biotechnology ETF Newsroom

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

MT NewswiresDec 2 22:14

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday Ahead of Week Promising Crucial Economic Data

MT NewswiresDec 2 21:37

The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?

Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.

wallstreetcnDec 1 12:38

Barclays's 'Bang-for-the-buck' Tail Hedging ETFs: HYG, XLF, IYR

Seeking AlphaNov 30 01:31

Sector Update: Health Care Stocks Advance Pre-Bell Friday

MT NewswiresNov 29 22:17

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of US Farm Prices Data

MT NewswiresNov 29 21:18

How to adjust the new national medical insurance catalog? Here is the explanation.

1. The success rate is 76%, with an average decline of 63%. This year, the success rate and decline of negotiating/bidding pharmaceuticals are basically equivalent to previous years; 2. This year, the fund calculation will pay more attention to the impact on fund expenditure, while also enhancing the comprehensiveness and scientific nature of the calculation work; 3. This year's catalog adjustment places more emphasis on the actual clinical needs and patients' actual medication, highlighting support for true innovation.

cls.cnNov 28 21:54

RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330

BenzingaNov 28 01:02 · Ratings

Amgen Analyst Ratings

BenzingaNov 28 01:01 · Ratings

Sector Update: Health Care Stocks Rise Pre-Bell Wednesday

MT NewswiresNov 27 22:11

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Crucial Inflation Data

MT NewswiresNov 27 21:06

Trump Taps Jay Bhattacharya to Lead National Institutes of Health

Seeking AlphaNov 27 19:23

Amgen weight loss drugs have a remarkable effect of reducing 20% body weight, but with relatively high side effects, leading to a temporary large drop of over 12% during trading hours.

Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.

wallstreetcnNov 27 07:22

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

BenzingaNov 27 05:06

Regeneron Pharmaceuticals Unusual Options Activity

BenzingaNov 27 04:20

Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?

BenzingaNov 27 02:27

Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs

Seeking AlphaNov 27 02:03

Amgen Decline on MariTide Data Could Be Due to Lack of More Details

Seeking AlphaNov 27 01:16

BioNTech Analyst Ratings

BenzingaNov 26 22:39 · Ratings

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT NewswiresNov 26 22:14